Targeting KRAS in NSCLC: Old Failures and New Options for "Non-G12c" Patients.

Jacobs, Francesca; Cani, Massimiliano; Malapelle, Umberto; Novello, Silvia; Napoli, Valerio Maria; Bironzo, Paolo

Jacobs, Francesca; Cani, Massimiliano; Malapelle, Umberto; Novello, Silvia; Napoli, Valerio Maria; Bironzo, Paolo.

Afiliação

Jacobs F; Department of Oncology, University of Turin, AOU San Luigi Gonzaga, 10043 Turin, Italy.
Cani M; Department of Oncology, University of Turin, AOU San Luigi Gonzaga, 10043 Turin, Italy.
Malapelle U; Department of Public Health, University of Naples Federico II, 80138 Naples, Italy.
Novello S; Department of Oncology, University of Turin, AOU San Luigi Gonzaga, 10043 Turin, Italy.
Napoli VM; Department of Oncology, University of Turin, AOU San Luigi Gonzaga, 10043 Turin, Italy.
Bironzo P; Department of Oncology, University of Turin, AOU San Luigi Gonzaga, 10043 Turin, Italy.

Cancers (Basel) ; 13(24)2021 Dec 16.

Article em En | MEDLINE | ID: mdl-34944952

Palavras-chave

G12C; KRAS; NSCLC; drug resistance; non-G12C; oncogene; targeted therapy

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Itália País de publicação: Suíça

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google